No Data
No Data
As of July 10th, Fujilai (301258.SZ) has a total of 13,733 shareholders.
On July 11th, Gelunhui reported that as of July 10th, 2024, the total number of shareholders of Fujilai (301258.SZ) was 13,733 on the investor interaction platform.
Fujilai (301258.SZ): No business related to research and development of innovative drugs at the moment.
On July 9th, Gelunhui reported that Fujilai (301258.SZ) stated on the investor platform that the company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients and health product ingredients. The main products include the thioctic acid series, phosphatidylcholine series, and peptide series. Currently, the company does not have any business related to innovative drugs.
Fujilai (301258.SZ): The company has achieved mass production of R-Octanoic acid produced by biocatalytic method.
On June 21, Gelunhui reported that Fujilai (301258.SZ) announced on the investor interaction platform that its biocatalytic production of R-thioctic acid has been put into mass production. It is mainly used for external sales and preparation of R-thioctic acid sodium salt. Currently, it is still in the market promotion stage, and whether it can completely replace the original process depends on market demand, customer acceptance, and other factors. In 2023, the revenue from this type of business will account for no more than 3% of the company's total revenue, with a relatively small proportion, and there are no clear expansion plans yet.
Fujilai (301258.SZ): Cumulatively repurchased 89,000 shares.
Fujilai (301258.SZ) announced that as of May 31, 2024, the company has repurchased a cumulative total of 89,400 shares of the company through the share buyback special securities account in the form of centralized bidding trading, accounting for 0.0975% of the company's current total share capital. The highest fill price is 25.28 yuan/share, and the lowest fill price is 21.68 yuan/share, using a total amount of 2,007,640.00 yuan (excluding transaction fees).
Fujilai (301258.SZ) plans to distribute 6.005202 yuan per 10 shares on June 12th after ex-rights and ex-dividends.
Fujilai (301258.SZ) announced that the company's 2023 annual equity distribution plan is: to distribute 10 shares to all shareholders ...
Suzhou Fushilai Pharmaceutical Co., Ltd. (SZSE:301258) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Suzhou Fushilai Pharmaceutical's (SZSE:301258) stock increased significantly by 38% over the past month. However, we decided to pay attention to the company'
No Data